Novel biomedical risk markers for cardiovascular disease.
Molecular moieties within newly discovered pathophysiological pathways in atherothrombosis represent potential biomedical risk markers for cardiovascular disease. Their discovery is important in that a large proportion of cardiovascular disease is unexplained by 'conventional' risk markers, and that novel markers may pave the way to new targets for intervention. Many candidate markers have been identified, among which inflammatory and haemostatic factors are prominent. This review will examine the evidence for the roles of key novel risk markers in cardiovascular disease, against criteria which define causality as well as potential clinical utility.
Magliano
Dianna J
DJ
Department of Epidemiology and Preventive Medicine, Central and Eastern Clinical School, Monash University, Melbourne, Victoria, Australia. dianna.magliano@med.monash.edu.au
Liew
Danny
D
Ashton
Emma L
EL
Sundararajan
Vijaya
V
McNeil
John J
JJ
D015415:Biomarkers; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D015815:Cell Adhesion Molecules / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006710:Homocysteine / Q000378:metabolism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D020097:Natriuretic Peptide, Brain / Q000378:metabolism; D012307:Risk Factors; D014841:von Willebrand Factor / Q000378:metabolism
D015415:Biomarkers; D015815:Cell Adhesion Molecules; D015850:Interleukin-6; D014841:von Willebrand Factor; D006710:Homocysteine; D020097:Natriuretic Peptide, Brain; D005340:Fibrinogen; D002097:C-Reactive Protein